This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Derica Rice Biography and Net Worth

EVP of Eli Lilly and Company

Derica W. Rice is the former Executive Vice President of CVS Health Corporation, a provider of health services and plans in the United States, and former President of CVS Caremark, the pharmacy benefits management business of CVS Health Corporation. He served in those positions from March 2018 to February 2020. Mr. Rice previously held several other executive level positions over nearly three decades with Eli Lilly and Company, a pharmaceutical company, including Executive Vice President, Global Services from January 2010 through December 2017 and Chief Financial Officer from May 2006 through December 2017. He also previously served on Target Corporation’s board of directors from September 2007 to January 2018.

What is Derica W. Rice's net worth?: The estimated net worth of Derica W. Rice is at least $42.79 million as of February 3rd, 2017. Mr. Rice owns 58,443 shares of Eli Lilly and Company stock worth more than $42,791,965 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Rice may own. Learn More about Derica W. Rice's net worth.
How do I contact Derica W. Rice?: The corporate mailing address for Mr. Rice and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Derica W. Rice's contact information.
Has Derica W. Rice been buying or selling shares of Eli Lilly and Company?: Derica W. Rice has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, Derica W. Rice sold 11,162 shares of the business's stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $77.14, for a transaction totalling $861,036.68. Following the completion of the sale, the executive vice president now directly owns 58,443 shares of the company's stock, valued at $4,508,293.02. Learn More on Derica W. Rice's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 31 times. They sold a total of 2,074,936 shares worth more than $21,628,352,978.48. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 1/31/2024.

Derica W. Rice Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/3/2017	Sell	11,162	$77.14	$861,036.68	58,443
2/3/2016	Sell	10,483	$77.78	$815,367.74	36,931
2/4/2015	Sell	5,316	$70.00	$372,120.00
2/2/2015	Sell	10,068	$71.84	$723,285.12

Derica W. Rice Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $732.20

$728.79

$752.64

50 Day Range

MA: $763.40

$726.31

$792.28

2 Week Range

Now: $732.20

$370.68

$800.78

Volume

2,052,626 shs

Average Volume

2,303,675 shs

Market Capitalization

$695.71 billion

P/E Ratio

126.24

Dividend Yield

0.70%

Beta

0.34